Abk�rzung zur Hauptnavigation Abk�rzung zu den Newsmeldungen Abk�rzung zu den Topstories  
  Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
ccc_logo_en.gif
 
AKH Wien
 
 
Hauptnavigation
  • Livestream 2021
  • Home
  • Über das CCC
    • Allgemeines
    • Leitung der Organisationseinheit
    • CCC-Office Team
    • Kliniken und Partner
    • Qualitätsmanagement
    • Kontakt
  • PatientInnen
    • Covid-19
    • Allgemeines
    • Cancer School
    • Terminvereinbarung
    • Pflegeambulanz
    • PatientInnenvertretung
    • Links
  • Klinischer Bereich
    • Allgemeines
    • CCC Tumorboards
  • Wissenschaft & Forschung
    • Young CCC
    • CCC-ExpertInnenvideos
    • CCC Forschungscluster
    • CCC Units
    • CCC Platforms
    • Translationale Forschung
    • CCC Best Paper Award
    • CCC-TRIO Symposium
    • Kontakt/Links
  • Lehre
    • CCC Cancer School
    • Vienna International Summer School on Clinical and Experimental Oncology - VSSO
    • CCC Excellence Lecture
    • Interdisziplinäre onkologische Ausbildung
    • Klinisch-Praktisches Jahr (KPJ)
    • PhD Programme
    • Postgraduelle Fort- und Weiterbildung
    • Information/Contact
 
 
Subnavigation
    Inhaltsbereich


    Zurück zur Übersicht
    Acta neuropathologica communications. 2022 Feb 12. doi: 10.1186/s40478-022-01314-x. pii: 10.1186/s40478-022-01314-x
    A postzygotic de novo NCDN mutation identified in a sporadic FTLD patient results in neurochondrin haploinsufficiency and altered FUS granule dynamics.
    Nicolas G1,  Sévigny M2,  Lecoquierre F3,  Marguet F4,  Deschênes A5,  Del Pelaez MC6,  Feuillette S7,  Audebrand A8,  Lecourtois M9,  Rousseau S10,  Richard AC11,  Cassinari K12,  Deramecourt V13,  Duyckaerts C14,  Boland A15,  Deleuze JF16,  Meyer V17,  Clarimon Echavarria J18,  Gelpi E19,  Akiyama H20,  Hasegawa M21,  Kawakami I22,  Wong TH23,  Van Rooij JGJ24,  Van Swieten JC25,  Campion D26,  Dutchak PA27,  Wallon D28,  Lavoie-Cardinal F29,  Laquerrière A30,  Rovelet-Lecrux A31,  Sephton CF32
    Author information
    1Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
    2Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
    3Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
    4Inserm U1245 and CHU Rouen, Department of Pathology, Normandie University, UNIROUEN, F-76000, Rouen, France.
    5Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
    6Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
    7Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
    8Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
    9Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
    10Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
    11Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
    12Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
    13Lille Neuroscience and Cognition (Inserm UMRS1172) Alzheimer and Tauopathies, Laboratory of Excellence Distalz (Development of Innovative Strategies for a Transdisciplinary Approach to ALZheimer's Disease), University of Lille, CHU Lille, Lille, France.
    14INSERM, CNRS U1127, Institut du Cerveau, Sorbonne Université, ICM, Paris, France.
    15CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
    16CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
    17CEA, Centre National de Recherche en Génomique Humaine, Université Paris-Saclay, 91057, Evry, France.
    18Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain.
    19Neurological Tissue Bank of the Biobank-Hospital Clinic-IDIBAPS, Barcelona, Spain.
    20Dementia Research Project, Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya City, Japan.
    21Dementia Research Project, Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya City, Japan.
    22Dementia Research Project, Department of Brain and Neurosciences, Tokyo Metropolitan Institute of Medical Science, Setagaya City, Japan.
    23Department of Neurology and Alzheimer Center, Erasmus Medical Center, Rotterdam, The Netherlands.
    24Department of Neurology and Alzheimer Center, Erasmus Medical Center, Rotterdam, The Netherlands.
    25Department of Neurology and Alzheimer Center, Erasmus Medical Center, Rotterdam, The Netherlands.
    26Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France.
    27Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
    28UNIROUEN, Inserm U1245 and CHU Rouen, Department of Neurology and CNR-MAJ, Normandie University, F-76000, Rouen, France.
    29Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6.
    30Inserm U1245 and CHU Rouen, Department of Pathology, Normandie University, UNIROUEN, F-76000, Rouen, France.
    31Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, Normandie University, UNIROUEN, F-76000, Rouen, France. anne.roveletlecrux@univ-rouen.fr.
    32Department of Psychiatry and Neuroscience, Laval University, Quebec City, QC, Canada, 2325, rue de l'Université, G1V 0A6. chantelle.sephton.1@ulaval.ca.
    Abstract

    Frontotemporal dementia (FTD) is a heterogeneous clinical disorder characterized by progressive abnormalities in behavior, executive functions, personality, language and/or motricity. A neuropathological subtype of FTD, frontotemporal lobar degeneration (FTLD)-FET, is characterized by protein aggregates consisting of the RNA-binding protein fused in sarcoma (FUS). The cause of FTLD-FET is not well understood and there is a lack of genetic evidence to aid in the investigation of mechanisms of the disease. The goal of this study was to identify genetic variants contributing to FTLD-FET and to investigate their effects on FUS pathology. We performed whole-exome sequencing on a 50-year-old FTLD patient with ubiquitin and FUS-positive neuronal inclusions and unaffected parents, and identified a de novo postzygotic nonsense variant in the NCDN gene encoding Neurochondrin (NCDN), NM_014284.3:c.1206G > A, p.(Trp402*). The variant was associated with a ~ 31% reduction in full-length protein levels in the patient's brain, suggesting that this mutation leads to NCDN haploinsufficiency. We examined the effects of NCDN haploinsufficiency on FUS and found that depleting primary cortical neurons of NCDN causes a reduction in the total number of FUS-positive cytoplasmic granules. Moreover, we found that these granules were significantly larger and more highly enriched with FUS. We then examined the effects of a loss of FUS function on NCDN in neurons and found that depleting cells of FUS leads to a decrease in NCDN protein and mRNA levels. Our study identifies the NCDN protein as a likely contributor of FTLD-FET pathophysiology. Moreover, we provide evidence for a negative feedback loop of toxicity between NCDN and FUS, where loss of NCDN alters FUS cytoplasmic dynamics, which in turn has an impact on NCDN expression.


    © 2022. The Author(s).

    KEYWORDS: Cytoplasmic granules, De novo mutation, FTLD-FET, FUS (fused in sarcoma), Frontotemporal dementia (FTD), Genetic variant, NCDN (neurochondrin), Neurodegeneration, Norbin, mGluR1/5

    Publikations ID: 35151370
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
    -- Initiative Krebsforschung / Krebsforschungslauf

    -- Cancer Care
    -- Kliniken und Partner
    -- CCC Cancer School
    -- Young CCC
    -- CCC Tumorboards
    -- CCC Forschungscluster
    -- CCC Units
    -- CCC Platforms
    -- SOPs / Leitlinien
    -- Kontakt
    Zuklappen
     
    Ausklappen
     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt